Monday, January 09, 2012

UK cost agency wants more data on Bayer's anti-clot drug | Reuters

Jan 9 (Reuters) - Britain's health costs watchdog is asking Bayer for more information on its anti-clotting drug Xarelto before deciding whether to recommend it for use on the state health service.

The National Institute for Health and Clinical Excellence (NICE) said data provided so far by Bayer on the drug, known generically as rivaroxaban, were not enough to judge whether it would be cost effective for prevention of strokes and embolisms in people with a heart condition known as atrial fibrillation.

"Evidence of rivaroxaban's cost-effectiveness was not reflective of all the people with atrial fibrillation in the UK who would be eligible for treatment with the drug," the watchdog said in a statement on Monday.

Posted via email from Jack's posterous

No comments: